KLF2 can differentially regulate endothelial genes, thus, it was considered as a key “molecular switch” governing endothelial function in vascular health and disease9, 10, 21. The observations presented here reveal that TA is a novel KLF2 activator and suggest that KLF2 could serve as a promising therapeutic target for the treatment of endothelial inflammation-associated cardiovascular disease.